ATE328603T1 - Modulatoren von polysacchariden und deren verwendungen - Google Patents

Modulatoren von polysacchariden und deren verwendungen

Info

Publication number: ATE328603T1
Authority: AT; Austria
Prior art keywords: glycosaminoglycan; peptides; sulfate; chitosan; mediated processes
Prior art date: 1999-03-26

Application number

AT00919594T

Other languages

English (en)

Inventor

Akira Takashima

Mark E Mummert

Mansour Mohamadzadeh

Original Assignee

Univ Texas

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-03-26

Filing date

2000-03-22

Publication date

2006-06-15

2000-03-22 Application filed by Univ Texas filed Critical Univ Texas

2006-06-15 Application granted granted Critical

2006-06-15 Publication of ATE328603T1 publication Critical patent/ATE328603T1/de

Links

150000004676 glycans Chemical class 0.000 title 1
229920001282 polysaccharide Polymers 0.000 title 1
239000005017 polysaccharide Substances 0.000 title 1
229920002683 Glycosaminoglycan Polymers 0.000 abstract 5
102000004196 processed proteins & peptides Human genes 0.000 abstract 5
108090000765 processed proteins & peptides Proteins 0.000 abstract 5
229920001661 Chitosan Polymers 0.000 abstract 2
208000015181 infectious disease Diseases 0.000 abstract 2
KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 abstract 2
230000001404 mediated effect Effects 0.000 abstract 2
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 1
SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 abstract 1
229920002101 Chitin Polymers 0.000 abstract 1
229920001287 Chondroitin sulfate Polymers 0.000 abstract 1
229920000045 Dermatan sulfate Polymers 0.000 abstract 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 1
229920000288 Keratan sulfate Polymers 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
230000008827 biological function Effects 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 abstract 1
229940059329 chondroitin sulfate Drugs 0.000 abstract 1
AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 abstract 1
229940051593 dermatan sulfate Drugs 0.000 abstract 1
230000006806 disease prevention Effects 0.000 abstract 1
239000003623 enhancer Substances 0.000 abstract 1
230000006870 function Effects 0.000 abstract 1
229920000669 heparin Polymers 0.000 abstract 1
229960002897 heparin Drugs 0.000 abstract 1
229920002674 hyaluronan Polymers 0.000 abstract 1
229960003160 hyaluronic acid Drugs 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
239000003068 molecular probe Substances 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Transplantation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicinal Preparation (AREA)
Polyesters Or Polycarbonates (AREA)

AT00919594T 1999-03-26 2000-03-22 Modulatoren von polysacchariden und deren verwendungen ATE328603T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US12647599P	1999-03-26	1999-03-26

Publications (1)

Publication Number	Publication Date
ATE328603T1 true ATE328603T1 (de)	2006-06-15

Family

ID=22425031

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00919594T ATE328603T1 (de)	1999-03-26	2000-03-22	Modulatoren von polysacchariden und deren verwendungen

Country Status (13)

Country	Link
US (2)	US6653285B1 (de)
EP (1)	EP1165112B1 (de)
JP (1)	JP2002540161A (de)
AT (1)	ATE328603T1 (de)
AU (1)	AU774650B2 (de)
CA (1)	CA2366604A1 (de)
CY (1)	CY1105531T1 (de)
DE (1)	DE60028558T2 (de)
DK (1)	DK1165112T3 (de)
ES (1)	ES2265928T3 (de)
MX (1)	MXPA01009690A (de)
PT (1)	PT1165112E (de)
WO (1)	WO2000057896A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2002258749A1 (en) *	2001-03-21	2002-10-08	The University Of Texas System	Inhibitors of glycosaminoglycans
US20040259783A1 (en) *	2001-11-09	2004-12-23	Tony Cruz	Pharmaceutical compositions of marine sponge microciona prolifera
ITPD20020003A1 (it)	2002-01-11	2003-07-11	Fidia Advanced Biopolymers Srl	Biomateriali a base di acido ialuronico come terapia anti-angiogenicanella cura dei tumori.
WO2005016364A1 (en) *	2003-08-14	2005-02-24	Guthy-Renker Corporation	Skin care composition including hexapeptide complexes and methods of their manufacture
US20060198800A1 (en) *	2003-08-14	2006-09-07	Natalie Dilallo	Skin care compositions including hexapeptide complexes and methods of their manufacture
MX344076B (es)	2008-06-30	2016-12-05	Esbatech Alcon Biomed Res Unit	Polipeptidos funcionalizados.
EP2307440A4 (de) *	2008-07-01	2012-12-19	Zacharon Pharmaceuticals Inc	Heparansulfathemmer
US8809009B2 (en)	2009-01-02	2014-08-19	Biomarin Pharmaceutical Inc.	Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker
US9029530B2 (en) *	2009-01-02	2015-05-12	Biomarin Pharmaceutical Inc.	Detection of oligosaccharides
US8592140B2 (en)	2009-01-02	2013-11-26	Biomarin Pharmaceutical Inc.	Detection of oligosaccharides
US8232073B2 (en)	2009-01-02	2012-07-31	Zacharon Pharmaceuticals, Inc.	Quantification of non-reducing end glycan residual compounds
WO2011094731A2 (en) *	2010-02-01	2011-08-04	The Board Of Trustees Of The Leland Stanford Junior University	Methods for diagnosis and treatment of non-insulin dependent diabetes mellitus
EP3249662B1 (de) *	2016-05-27	2020-05-13	Hanning Elektro-Werke GmbH & Co. KG	Elektrischer pumpenmotor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9207949D0 (en) *	1992-04-09	1992-05-27	Univ Manitoba	Molecular cloning of a novel hyaluronan receptor that mediates tumor cell motility
US5981478A (en) *	1993-11-24	1999-11-09	La Jolla Cancer Research Foundation	Integrin-binding peptides
CA2237051A1 (en) *	1997-12-19	1999-06-19	Eva A. Turley	Enhanced affinity hyaluronan binding peptides
EP1324765A1 (de) *	2000-10-05	2003-07-09	Transition Therapeutics Inc.	Zusammensetzungen und verfahren zur beeinflussung der zellulären antwort auf verletzungen und auf andere von hyaladherin und hyaluronan regulierte zellproliferationsstörungen

2000
- 2000-03-22 MX MXPA01009690A patent/MXPA01009690A/es active IP Right Grant
- 2000-03-22 CA CA002366604A patent/CA2366604A1/en not_active Abandoned
- 2000-03-22 EP EP00919594A patent/EP1165112B1/de not_active Expired - Lifetime
- 2000-03-22 JP JP2000607646A patent/JP2002540161A/ja active Pending
- 2000-03-22 ES ES00919594T patent/ES2265928T3/es not_active Expired - Lifetime
- 2000-03-22 DK DK00919594T patent/DK1165112T3/da active
- 2000-03-22 AU AU40255/00A patent/AU774650B2/en not_active Ceased
- 2000-03-22 WO PCT/US2000/007813 patent/WO2000057896A1/en not_active Ceased
- 2000-03-22 PT PT00919594T patent/PT1165112E/pt unknown
- 2000-03-22 AT AT00919594T patent/ATE328603T1/de not_active IP Right Cessation
- 2000-03-22 DE DE60028558T patent/DE60028558T2/de not_active Expired - Fee Related
- 2000-03-22 US US09/532,709 patent/US6653285B1/en not_active Expired - Fee Related
2003
- 2003-10-06 US US10/680,670 patent/US6923965B2/en not_active Expired - Fee Related
2006
- 2006-08-23 CY CY20061101185T patent/CY1105531T1/el unknown

Also Published As

Publication number	Publication date
AU774650B2 (en)	2004-07-01
CA2366604A1 (en)	2000-10-05
DE60028558T2 (de)	2007-05-16
EP1165112A4 (de)	2002-09-25
WO2000057896A1 (en)	2000-10-05
ES2265928T3 (es)	2007-03-01
DK1165112T3 (da)	2006-10-09
US20040138105A1 (en)	2004-07-15
DE60028558D1 (de)	2006-07-20
MXPA01009690A (es)	2003-06-24
AU4025500A (en)	2000-10-16
EP1165112B1 (de)	2006-06-07
EP1165112A1 (de)	2002-01-02
CY1105531T1 (el)	2010-07-28
PT1165112E (pt)	2006-10-31
JP2002540161A (ja)	2002-11-26
US6923965B2 (en)	2005-08-02
US6653285B1 (en)	2003-11-25

Similar Documents

Publication	Publication Date	Title
ATE328603T1 (de)	2006-06-15	Modulatoren von polysacchariden und deren verwendungen
JP2003522732A5 (de)	2007-02-08
NZ333925A (en)	2000-07-28	Use of heparin or heparan sulphate in combination with chitosan for the prevention or treatment of infections caused by herpes virus
JP2006502129A5 (de)	2006-06-15
DE69533370D1 (de)	2004-09-16	Heparinähnliche sulfatierte Polysaccharide
AU6339599A (en)	2000-05-01	Quinoline derivatives and their use as antibacterial agents
WO2007070547A3 (en)	2007-08-16	Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid
FR11C0037I2 (fr)	2012-06-22	Antibiotiques macrolides et traitement de la pasteurellose
EP1689348A4 (de)	2008-11-26	Oligosaccharid-zusammensetzungen und ihre verwendung bei der behandlung von infektionen
BR9607516A (pt)	1997-12-30	Processo para o revestimento de objetos com ácido hialuronico derivados dos mesmos e polimeros semi-sintéticos
CY1109437T1 (el)	2014-08-13	ΣΥΝΘΕΣΕΙΣ β-ΓΛΥΚΑΝΩΝ ΚΑΙ ΕΙΔΙΚΩΝ ΑΝΟΣΟΣΦΑΙΡΙΝΩΝ
EP1427744A4 (de)	2005-12-07	System zur antikörperexpression und- synthese
BR9912653A (pt)	2001-05-02	Vìrus de herpes atenuado, cepa de vìrus, célula dendrìtica, processo para produzir um célula, composição farmacêutica, uso de um vìrus, e, processo para executar a terapia de gene em um paciente humano ou animal ou para tratar ou prevenir uma infecção patogênica ou câncer para tratar paciente animal
BR0013010B1 (pt)	2013-12-10	Formulação aquosa de cloreto de sódio de moxifloxacina, processo para sua preparação e aplicação da referida formulação, bem como preparado de combinação e aplicação de uma solução aquosa de cloridrato de moxifloxacina
BR0307508A (pt)	2004-12-07	Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de tratamento de doença
BRPI0306993B8 (pt)	2021-05-25	polímero de polialquilenoglicol ativado; composição; e uso de um composto na produção de um medicamento para o tratamento de esclerose múltipla ou infecção viral suscetível
EA200000911A1 (ru)	2001-04-23	Новые кристаллические формы антивирусного соединения бензимидазола
DE69727142D1 (de)	2004-02-12	Verwendung eines bpi proteinproduktes als antithrombotisches mittel
BR9509434A (pt)	1998-01-06	Agente de aglutinação uso do mesmo composição farmacêutica e processo de tratamento de uma doença inflamatória autoimune ou alérgica
BR0012087A (pt)	2002-04-02	Composições compreendendo copolìmeros em bloco hidrogenados e aplicações de uso final dos mesmos
BR9508323A (pt)	1998-01-06	Uso de quitosan e um polissacarídeo imobilizado no mesmo escolhido dentre heparina sulfato de herpan e sulfato de extran e processo para impedir ou reduzir substancialmente a adesão indesejável de tecidos com relação à cicatrização de feridas
IS7193A (is)	2004-03-22	Lyfjablanda með kítósan óligómerum
BR9808100A (pt)	2000-03-08	Utilização de amandantina para tratamento de hepatite c.
DE69530844D1 (de)	2003-06-26	Verfahren und substanzen gegen protozoen
DE69316758D1 (de)	1998-03-05	Selbstvernetztes gellangummi

Legal Events

Date

Code

Title

Description

2007-04-15

UEP

Publication of translation of european patent specification

Ref document number: 1165112

Country of ref document: EP

2010-12-15

REN

Ceased due to non-payment of the annual fee